JB/CALL/IDORSIA/8/0.25/20.09.24 Stock

Warrant

IDYVJB

CH1272326500

Market Closed - Swiss Exchange 11:15:01 2024-06-18 EDT
0.01 ^CHF	-50.00%

1 month	-83.33%
3 months	-94.08%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Latest news about IDORSIA LTD

New semester, new state of mind	07-01
Idorsia Wins European Commission's Nod for Resistant Hypertension Treatment	07-01	MT
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension	07-01	GL
Idorsia Ltd Receives Approval from the European Commission for JERAYGO?	07-01	CI

More news

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	Bank Julius Bär
	IDYVJB
ISIN	CH1272326500
Date issued	2023-06-09
Strike	8 CHF
Maturity	2024-09-20 (77 Days)
Parity	4 : 1
Emission price	0.66 CHF
Emission volume	N/A
Settlement	Ambos
Currency	CHF

Technical Indicators

Highest since issue	0.76 CHF
Lowest since issue	0.01 CHF
Delta	0.06x
Omega	4.338
Premium	275.14x
Gearing	76.43x
Moneyness	0.2675
Difference Strike	5.86 CHF
Difference Strike %	+73.25%
Spread	0.01 CHF
Spread %	83.33%
Theoretical value	0.007000
Implied Volatility	148.86 %
Total Loss Probability	98.83 %
Intrinsic value	0.000000
Present value	0.007000
Break even	8.028 CHF
Theta	-0x
Vega	0x
Rho	0x

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company